Latest Intelligence on Pharmaceutical Manufacturers

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Chiron: TOBI reduces cystic fibrosis hospitalizations

Chiron has shown that subjects undergoing TOBI treatment are less likely to be hospitalized for respiratory symptoms or to be treated with oral antibiotics than those undergoing routine care alone. Pharma companies are increasingly targeting restricted patient populations as development costs continue to rise.<BR />

Published By Datamonitor
04 Jun 2003
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Novartis: Ritalin LA more effective than Concerta

A recent head-to-head trial found that a new extended release formulation of Novartis' Ritalin was more effective in the treatment of attention deficit/hyperactivity disorder (ADHD) than McNeil Consumer & Specialty Pharmaceutical's Concerta, one of the market leaders. Despite this, the sustained release technology of Concerta is expected to keep the drug ahead of methylphenidate compounds.

Published By Datamonitor
10 Jun 2003
CommentWire
CommentWire

Novartis: Glivec en route to blockbuster status

According to recent research, newly diagnosed patients with chronic myeloid leukaemia are nine times more likely to achieve a complete cytogenetic response when treated with Novartis' [NVS] Glivec than when treated with traditional combination therapy. The continued positive results mean that Glivec looks set to become a blockbuster.

Published By Datamonitor
10 Jun 2003
CommentWire
CommentWire

Aventis: OTC is not the answer

The widespread availability of generic loratadine has made patients and third-party payers reluctant to accept premium-priced allergy treatments that cannot demonstrate a significant clinical advantage. There is potential for Aventis' [AVE] Allegra to remain competitive after patent expiry if it negates the OTC approach and opts for targeted marketing and continual investment in the product.

Published By Datamonitor
11 Jun 2003
CommentWire
CommentWire

Eli Lilly: Cymbalta cannot falter

Lilly's [LLY] claim to be on track for both its financial targets and the launch of antidepressant Cymbalta resulted in a share price rise of 5%. The progress of Cymbalta is a good sign. The drug has the potential to be a major earner and Lilly needs new successful products to pull itself out of a two-year earnings slump.

Published By Datamonitor
12 Jun 2003
CommentWire
CommentWire

Wrigley: Viagra gum raises expectations

If Wrigley [WWY] is to bring its Viagra gum to market before 2011 it will need to negotiate hard with Pfizer [PFE], which holds the Viagra patent until then. If the product does come to market, demand will undoubtedly be high. If a success, the technology of implanting drugs in gum could increase in popularity and potentially be used for more valuable healthcare applications.<BR />

Published By Datamonitor
16 Jun 2003
CommentWire
CommentWire

Johnson & Johnson: contraceptive patch to shake up market

The continuing rollout of J&J's Evra marks an important development in the $4 billion hormonal contraception market. Oral pills have dominated the market for more than 40 years, but with competitive pricing, convenient dosing and the support of family planning organizations, the consumer friendly patch could shake everything up.

Published By Datamonitor
18 Jun 2003
CommentWire
CommentWire

Nektar: Exubera trials alleviate concerns

Pfizer [PFE], Aventis [AVE] and Nektar Therapeutics [NKTR] are working together to market the first inhalable insulin - a potentially welcome alternative to the injectable insulins used by diabetics today. The drug has suffered a number of setbacks, including worries over it leading to reduced lung function. However, Nektar's latest trial results should go some way to alleviating concerns.

Published By Datamonitor
18 Jun 2003
Expert View
Expert View

Convincing the healthy to get vaccinated

The launch of Wyeth [WYE] and MedImmune's [MEDI] new nasally delivered vaccine, FluMist, could be a milestone in the evolution of the vaccine market, according to Datamonitor analyst Dr Amber Gibson. Key players will no longer be reliant on governments and health authorities, but can instead drive uptake through education and marketing campaigns, changing the skills needed for market success...

Published By Datamonitor
27 Jun 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.